HIV Medicine最新文献

{"title":"Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.","authors":"C Martorell, M Ramgopal, D Hagins, O Osiyemi, J R Arribas, M Berhe, Y Yazdanpanah, C Orkin, L Santiago, C Rosero, N Unger, H Liu, R Rogers, J T Hindman, A Wurapa","doi":"10.1111/hiv.70018","DOIUrl":"https://doi.org/10.1111/hiv.70018","url":null,"abstract":"<p><strong>Introduction: </strong>Black and Hispanic/Latine people are disproportionately affected by HIV-1 and may have a greater risk of comorbidities than non-Black and non-Hispanic/Latine people with HIV. However, they have historically been underrepresented in HIV clinical studies. We aimed to assess the efficacy and safety of first-line antiretroviral therapy with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) over 5 years in Black and Hispanic/Latine people with HIV.</p><p><strong>Methods: </strong>We present two post hoc pooled analyses of participants who received B/F/TAF up to week 240 in studies 1489 (NCT02607930) and 1490 (NCT02607956). Outcomes were compared between self-identified Black and non-Black participants and between Hispanic/Latine and non-Hispanic/Latine participants, including baseline characteristics, proportion with HIV-1 RNA <50 copies/mL, change in CD4 cell count, adherence, changes in metabolic parameters, and treatment-emergent adverse events.</p><p><strong>Results: </strong>Overall, 211 Black, 421 non-Black, 155 Hispanic/Latine, and 477 non-Hispanic/Latine participants received B/F/TAF up to week 240. At baseline, median ages were 30-34 years, and 84%-91% were male at birth. At week 240, high proportions of Black (97%), non-Black (99%), Hispanic/Latine (100%), and non-Hispanic/Latine (98%) participants had HIV-1 RNA <50 copies/mL. Black people with HIV were more likely than non-Black people with HIV to have low (<85%) adherence (11% vs. 5%; p = 0.0074). Changes in CD4 count, metabolic and renal parameters, and treatment-emergent hypertension and diabetes were generally similar between Black and non-Black and Hispanic/Latine and non-Hispanic/Latine participants. A smaller proportion of Black than non-Black people with HIV experienced study drug-related treatment-emergent adverse events (20% vs. 32%; p = 0.0026).</p><p><strong>Conclusions: </strong>These results demonstrate the durability and long-term safety of B/F/TAF in Black and Hispanic/Latine people with HIV.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing weight change in adolescents and young adults with perinatally acquired HIV and integrase inhibitor use.","authors":"Kathleen J Pincus, Nabila Faridi, Patrick Amadeus Ryscavage, Hyunuk Seung, Kristine A Parbuoni, Matthew Grant, Neha Sheth Pandit","doi":"10.1111/hiv.70019","DOIUrl":"https://doi.org/10.1111/hiv.70019","url":null,"abstract":"<p><strong>Introduction: </strong>Integrase strand transfer inhibitors (INSTIs) are the mainstay of treatment in adults and children living with HIV. Weight gain has been associated with INSTI use in adults; however, less data exist on its effects on younger patients. This study aimed to characterize the impact of INSTIs on weight in patients living with perinatally acquired HIV (PAHIV).</p><p><strong>Methods: </strong>Retrospective cohort study of patients with PAHIV maintained on an INSTI for ≥6 months. Descriptive statistics were used to illustrate baseline characteristics. A linear mixed model with spline at the time of INSTI initiation was used to evaluate the primary outcome of the change in body mass index (BMI) slope pre- and post-INSTI use.</p><p><strong>Results: </strong>Ninety-three patients with PAHIV who initiated INSTIs between June 2010 and September 2021 were included. The median age of INSTI initiation was 19.3 (±5.9) years. Before INSTI initiation, BMI showed a positive trend of 0.11 kg/m² per 6 months (p = 0.2); after INSTI initiation, it increased by 0.26 kg/m² per 6 months (p = 0.002). Although similar post-INSTI BMI increases were seen regardless of age at initiation, a significant BMI change was seen post-INSTI initiation in females, those on concomitant tenofovir alafenamide or other medications that cause weight gain, with baseline BMIs of underweight or healthy weight, bictegravir or dolutegravir exposure and those virologically suppressed at initiation.</p><p><strong>Conclusion: </strong>In this US cohort of patients with PAHIV initiated on INSTI, a sustained increase in the rate of BMI change was observed. Specific patient variables resulted in a statistically significant increase in weight gain after INSTI initiation.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DÖAK 2025 German Austrian AIDS Conference","authors":"","doi":"10.1111/hiv.70004","DOIUrl":"10.1111/hiv.70004","url":null,"abstract":"<p><b>DÖAK 2025 | German Austrian AIDS Conference</b></p><p><b>Hofburg Vienna</b></p><p><b>20–22 March 2025</b></p><p>EPIDEMIOLOGY &amp; PREVENTIVE MEDICINE</p><p>BASIC SCIENCE</p><p>HIV THERAPY</p><p>COMORBIDITIES &amp; STIs</p><p>LIVING WITH HIV &amp; PSYCHOSOCIAL HEALTH</p><p>POPULATIONS OF SPECIAL INTEREST</p><p>PUBLIC HEALTH, PREVENTION &amp; CAREMODELS</p><p>EXPERT SESSION: INFECTIOLOGY CASE DISCUSSION</p><p>EXPERT SESSION: CONNECT HIV RESEARCH</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 S1","pages":"3-82"},"PeriodicalIF":2.8,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143663575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Taxonomic and functional profile of the anorectal microbiota in HIV-positive and HIV-negative men who have sex with men, using a metagenomic approach.","authors":"Paula Natalia Hernández-Trujillo, Camila Andrea Lopez-Barón, Gabriela Arévalo-Pinzón, Martha Liliana Trujillo-Güiza, Martha Isabel González-Duque, Adriana Matilde Flórez, Diego C Franco, Javier Vanegas","doi":"10.1111/hiv.70014","DOIUrl":"https://doi.org/10.1111/hiv.70014","url":null,"abstract":"<p><strong>Introduction: </strong>The study of bacterial diversity in human samples is crucial for developing biomarkers of health and disease. This research characterized the taxonomic and functional diversity of the anorectal bacterial microbiota in men who hae sex with men (MSM) with HIV compared to men from this group without HIV.</p><p><strong>Materials and methods: </strong>In July and August 2023, self-collected anorectal swabs were obtained. DNA was extracted from each sample, and metagenomic sequencing was performed. With the obtained data, alpha and beta diversity, bacterial abundance, differential operational taxonomic units, and functional diversity were determined.</p><p><strong>Results: </strong>Initially, 90 samples were collected, with 20 discarded due to having less than 200 ng of DNA and 15 due to incomplete sequencing, leaving 55 samples analysed (15 HIV-positive and 40 HIV-negative). No significant differences were found between groups in terms of alpha diversity (Shannon index p = 0.45) and beta diversity (PERMANOVA R = -0.03). Prevotella was identified as the most abundant genus in both groups. Twelve genes were found to be more abundant in the anorectal microbiota of the HIV group, which promote bacterial growth, colonization and survival.</p><p><strong>Conclusion: </strong>Alterations in the anorectal microbiota could influence the pathogenesis of HIV and its complications in this population, underscoring the need to investigate these mechanisms and explore interventions to improve health. Longitudinal studies are needed to analyse changes in the anorectal microbiota during HIV infection and its response to treatment, integrating metagenomic, clinical, and immunological data to better understand the interactions between HIV, the microbiota and host health.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of mental health service use on the HIV care cascade among women.","authors":"Seerat Chawla, Angela Kaida, Marie-Josée Brouillette, Bluma Kleiner, Danièle Dubuc, Lashanda Skerritt, Ann N Burchell, Danielle Rouleau, Mona Loutfy, Alexandra de Pokomandy","doi":"10.1111/hiv.70008","DOIUrl":"https://doi.org/10.1111/hiv.70008","url":null,"abstract":"<p><strong>Background: </strong>While the negative effects of mental health issues on HIV clinical outcomes have been well-documented, the impact of mental health treatment on the HIV care cascade is largely uncharacterized. The objective of this study was to describe the engagement of women with mental health conditions and symptoms, who reported using mental health services, across the HIV care cascade and to assess the relationship between mental health service use and HIV care steps.</p><p><strong>Methods: </strong>Longitudinal data were analysed from participants enrolled in the Canadian HIV Women's Sexual and Reproductive Health Cohort Study (CHIWOS) (2013-2018) who had clinically significant depressive symptoms or reported a mental health diagnosis at baseline. Among this subset, four states of HIV care were defined at baseline, 18 months and 36 months: (1) unengaged in care (did not visit an HIV provider in the past year), (2) not on antiretroviral therapy (ART) (visited an HIV provider in the past year but did not report current ART use), (3) detectable (reported current ART use but a detectable viral load) and (4) optimal (reported current ART use and an undetectable viral load). Sankey diagrams were used to illustrate the engagement of women across the HIV care cascade over 3 years based on their self-reported use of mental health services at baseline. The association between mental health service use and care state at baseline was analysed using multinomial logistic regression models.</p><p><strong>Results: </strong>Of the 898 women in the cohort with significant depressive symptoms or mental health conditions at baseline, 3.8% (n = 34) were unengaged in care, 10.9% (n = 98) were not on ART, 12.4% (n = 111) were detectable and 72.9% (n = 655) were optimal. Over the 36 months, 51.0% of women transitioned between states at least once. When stratified by service use, women who reported use of mental health services at baseline had better engagement across the care cascade and had fewer transitions between states over the 3 years, 37.2% of which were to better states of care. The use of mental health services at baseline was also significantly associated with greater odds of engagement in the optimal state compared with not on ART (adjusted odds ratio [aOR]: 1.72, 95% confidence interval [CI]: 1.07-2.77). A similar but statistically insignificant association was found with the detectable care state (aOR: 1.67, 95% CI: 0.92-3.03).</p><p><strong>Conclusions: </strong>Our findings demonstrate that linkage to mental health care has a positive impact on HIV care outcomes among women. Accessible mental health services may serve to improve both mental well-being and progression of these patients along the HIV care cascade, thereby achieving individual and public health goals.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trend of HIV/AIDS disease burden in China from 1990 to 2021: An age-period-cohort model analysis.","authors":"Xiaxia He, Wenjie Zheng, Xin Wang, Yongpo Jiang, Weimin Zhu","doi":"10.1111/hiv.70009","DOIUrl":"https://doi.org/10.1111/hiv.70009","url":null,"abstract":"<p><strong>Background: </strong>Understanding the burden of HIV/AIDS in China over the last few decades is vital for creating effective control strategies.</p><p><strong>Methods: </strong>This study systematically retrieved data from the Global Burden of Disease (GBD) study 2021, including information related to HIV/AIDS in China. It assessed the burden of HIV/AIDS using specific indicators and methods, such as incidence, mortality and disability-adjusted life-years (DALYs). Joinpoint regression models were used to analyse the trends in disease burden, and age-period-cohort models were used to evaluate the effects of age, period and cohort.</p><p><strong>Results: </strong>From 1990 to 2021, the incidence, mortality and DALYs of HIV/AIDS in China increased for the total population, as well as for males and females. The age-standardized incidence, mortality and DALY rates rose at average annual rates of 0.051, 0.056 and 2.629, respectively. Age-period-cohort model analysis showed that net drift values for incidence, mortality and DALY rates across all age groups were greater than 0 (p < 0.05), with local drifts peaking between the ages of 20 and 24. The risk of HIV/AIDS increased with age. Compared with the 2005-2009 reference period, overall, male and female incidence risks first increased and then decreased, while mortality and DALY risks continued to rise. Additionally, the risks for the 1945-1949 birth cohort also showed an increasing trend.</p><p><strong>Conclusion: </strong>In conclusion, the overall HIV/AIDS burden in China grew from 1990 to 2021. To combat this, future efforts should focus on educating and preventing transmission among adolescents and the elderly.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipid nanoparticles in antiretroviral therapy: A nanotechnology breakthrough for HIV/AIDS treatment.","authors":"D Dulana C Suriyarachchi, Nuwanthi P Katuwavila","doi":"10.1111/hiv.13770","DOIUrl":"https://doi.org/10.1111/hiv.13770","url":null,"abstract":"<p><strong>Background: </strong>The development of an effective drug delivery system for the treatment of HIV/AIDS is a global challenge. The conventional drug delivery approach, namely highly active antiretroviral therapy (HAART), has increased the lifespan of HIV/AIDS patients. While antiretroviral drugs are critical for managing HIV/AIDS, they are not considered curative treatments and require additional supportive treatments depending on the clinical condition. Theoretically, all steps in the life cycle of HIV are potential targets for antiretroviral therapy. However, the eradication of HIV is still not possible with these approaches on account of some limitations. Lipid nanoparticles are effective in the delivery of antiretrovirals (ARVs) as they primarily lower the toxicity of ARVs and ease of scaling up and manufacturing, and also offer functionalization capabilities, targeted drug delivery, controlled release profiles and increased load capacity.</p><p><strong>Methods: </strong>Data were retrieved from various online electronic resources, including PubMed, Google Scholar and Scopus among others. Keywords such as 'lipid nanoparticles', 'antiretroviral therapy', 'HIV/AIDS' and 'nanomedicine' were used to formulate search strategies across approximately 106 research and review articles.</p><p><strong>Results: </strong>Lipid-based nanoparticles, including liposomes, solid lipid nanoparticles, nanostructured lipid carriers and hybrid lipid nanoparticles, have been reported as being an effective strategy for the delivery of anti-HIV drugs.</p><p><strong>Conclusions: </strong>This review discusses how lipidic nanoparticles can be used to deliver drugs to their target sites in an effective manner and considers the fate of lipid nanoparticles within the animal body.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143541787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting PrEP acceptability and self-efficacy among men who have sex with men in the UK: The roles of identity resilience, science mistrust, and stigma.","authors":"Anthony J Gifford, Rusi Jaspal, Bethany A Jones, Daragh T McDermott","doi":"10.1111/hiv.13768","DOIUrl":"https://doi.org/10.1111/hiv.13768","url":null,"abstract":"<p><strong>Introduction: </strong>Pre-exposure prophylaxis (PrEP) is medication used to prevent the spread of HIV. Populations with increased need of HIV prevention (e.g., men who have sex with men [MSM]) are eligible for free PrEP in the UK. However, HIV surveillance reports indicate stagnated uptake of the drug, alongside increasing rates of HIV acquisition. As such, psychosocial research is needed to explore the social barriers to PrEP uptake. This study aimed to explore the role of identity resilience (i.e., ability to maintain a positive and stable sense of self) as a predictor for PrEP usage. We hypothesized that PrEP self-efficacy (i.e., belief in one's ability to take PrEP) would be positively predicted by PrEP acceptability. We also hypothesized that identity worth and identity continuity (components of identity resilience) would be associated with PrEP acceptability and PrEP self-efficacy. These would be mediated by mistrust in science, PrEP stigma, and perceived risk of HIV.</p><p><strong>Methods: </strong>In total, 500 MSM who were assigned male at birth, were aged ≥18 years, and did not have HIV participated in an online cross-sectional, psychometric study between June and September 2023. Participants had to be based in the UK but could either be PrEP users or non-users. Structural equation modelling was used to explore a model of best fit to test the hypotheses.</p><p><strong>Results: </strong>Participants were aged 18-73 years (mean 35.61, standard deviation [SD] 9.95), mostly (91.2%) white, educated to an undergraduate level or above (70.9%), and non-users of PrEP (58.2%). Model fit was satisfactory: χ² = 4.51, degrees of freedom = 3, p-value = 0.209, comparative fit index 0.997, Tucker Lewis Index 0.972, root mean square of approximation 0.032, and standardized root mean square residual 0.011. Identity worth was positively associated with PrEP self-efficacy. Identity worth was indirectly associated with PrEP acceptability and PrEP self-efficacy. The positive association of identity worth and PrEP acceptability was mediated through lower mistrust of science and lower PrEP stigma but not perceived risk of HIV.</p><p><strong>Conclusions: </strong>Results indicate that the decision to take PrEP is associated with the constructs of identity worth (i.e., self-esteem, self-efficacy, and distinctiveness) rather than risk-based appraisals alone. The reasons for accessing and using PrEP may no longer be motivated by an inherent perceived risk of HIV acquisition. When trying to increase PrEP uptake, addressing specific parts of identity resilience may be beneficial. For example, therapeutic interventions (e.g., counselling) could include interventions to improve positive sexual identities and self-esteem.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection.","authors":"Charles Béguelin, Bernard Surial, Eveline Hofmann, Lorin Begré, Aline Munting, Huldrych F Günthard, Marcel Stöckle, Enos Bernasconi, Patrick Schmid, Alexandra Calmy, Franziska Suter-Riniker, Andri Rauch, Gilles Wandeler","doi":"10.1111/hiv.13766","DOIUrl":"https://doi.org/10.1111/hiv.13766","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatitis B surface antigen (HBsAg) loss is a rare event among persons with hepatitis B virus (HBV) monoinfection but seems to happen more frequently in people with HIV (PWH). We assessed the proportion of PWH/HBV coinfection who experienced HBsAg loss during long-term tenofovir-therapy and evaluated its association with quantitative HBsAg (qHBsAg) levels at tenofovir start.</p><p><strong>Methods: </strong>All Swiss HIV Cohort Study participants with two or more positive HBsAg measurements more than 6 months apart, and at least 4 years of tenofovir-containing antiretroviral therapy (ART), were considered. Our main outcomes were the loss of HBsAg during the first 2 years of tenofovir therapy and until the last available follow-up. We explored the association between qHBsAg levels at tenofovir start and HBsAg loss using multivariable logistic regression adjusted for potential confounders.</p><p><strong>Results: </strong>A total of 272 PWH and HBV coinfection were included. Median age was 41 years (IQR 36-46) and 81% (221) were men. At tenofovir start, 62% (169/272) received prior HBV active therapy, 49% (110/224) were hepatitis B e antigen (HBeAg)-positive, 82% (222/272) had detectable HBV DNA (median 4.0 log10 IU/mL, IQR 2.1-7.5) and 19% (46/242) had low qHBsAg, defined as <1000 IU/mL. HBsAg loss was observed in 7% (19/272) of participants during the first 2 years of tenofovir-containing ART and in 16% (43/272) after a median follow-up time of 8.4 years (IQR 2.6-15.8). At the last follow-up, 59% (16/27) of those with HBsAg loss had seroconverted for detectable anti-HBs antibodies. In multivariable analyses, low qHBsAg at tenofovir start (OR 5.3, 95% CI 1.6-17.8) was a significant predictor of HBsAg loss.</p><p><strong>Conclusion: </strong>We found high rates of HBsAg loss in PWH and HBV coinfection on long-term tenofovir-containing ART, most of whom had low qHBsAg at tenofovir start.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-risk human papillomavirus prevalence and serostatus in a cohort of cisgender women and people with a cervix living with perinatally acquired HIV.","authors":"Merle Henderson, Dierdre Lyons, Simon Beddows, Miranda Cowen, Kavita Panwar, Corrina Wright, Jacquie Ujetz, Ellie Crook, Hasit Patel, David Smith, Caroline Foster, Sarah Fidler, Tamara Elliott","doi":"10.1111/hiv.70001","DOIUrl":"https://doi.org/10.1111/hiv.70001","url":null,"abstract":"<p><strong>Objectives: </strong>Human papillomavirus (HPV)-associated cervical cancer risk is greater in people with HIV, although this has been at least partially attenuated by antiretroviral medication, enhanced cervical screening and HPV vaccination. People with perinatally acquired HIV may remain at higher risk due to lifelong immunosuppression and potentially reduced vaccine effectiveness. In this study in people with a cervix with perinatally acquired HIV, we explored cervical high-risk HPV (hrHPV) prevalence and HPV serostatus.</p><p><strong>Methods: </strong>Participants were recruited from a London HIV service between 2020 and 2022. Cervical samples from those sexually active were analysed for hrHPV (Cepheid GeneXpert) and cytology, and, if abnormal, a referral was made to colposcopy. Serum samples were tested for antibodies against HPV6/11/16/18/31/33/45/52/58. A self-reported questionnaire including HPV vaccination history was completed.</p><p><strong>Results: </strong>Fifty-seven people were recruited with a median age of 25 years (range 18-34). Of those providing a cervical sample, 15/47 (32%) were hrHPV-positive and 12/40 (30%) had abnormal cytology; 1/17 referred for colposcopy had CIN2 (6%); 7/15 (47%) with hrHPV were below the national screening age of 24.5 years (range 19-23), and 9/15 (60%) reported previous HPV vaccination. No vaccinated participants had hrHPV16/18. Of those vaccinated, 37/39 (95%) were seropositive for HPV16 and 30/39 (77%) for HPV18. Two vaccinated participants were seronegative for HPV16/18; both had detectable HIV viral loads and CD4 counts <200 cells/μL at recruitment.</p><p><strong>Conclusion: </strong>In this small observational study we identified a 32% prevalence of cervical hrHPV. Cervical screening and HPV vaccination remain vital in this group, with further data required to inform screening guidelines for this population.</p>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143500522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}